<DOC>
	<DOCNO>NCT00000967</DOCNO>
	<brief_summary>PRIMARY : To determine maximum tolerate dose interferon-alfa ( IFN-A ) alone combination zidovudine ( AZT ) ; assess safety tolerance IFN-A alone combination AZT . SECONDARY : To evaluate effect combination IFN-A AZT immunologic virologic parameter ; determine whether pharmacokinetic parameter AZT modify subcutaneous administration IFN-A . AZT effective suppress progression HIV infection patient without symptom AIDS AIDS-related complex ( ARC ) . However , use AZT limit frequent toxicity , sometimes relate amount drug give . Thus , combination treatment two drug work together may provide effective safer treatment . IFN-A drug antiviral effect may work well AZT .</brief_summary>
	<brief_title>The Safety Zidovudine Plus Interferon-Alpha HIV-Infected Children</brief_title>
	<detailed_description>AZT effective suppress progression HIV infection patient without symptom AIDS AIDS-related complex ( ARC ) . However , use AZT limit frequent toxicity , sometimes relate amount drug give . Thus , combination treatment two drug work together may provide effective safer treatment . IFN-A drug antiviral effect may work well AZT . The study conduct three stage . In Cohort A ( IFN-A alone ) , four patient receive IFN-A ; subsequent four-patient cohort receive dos escalate increment . If 50 percent patient dose level experience grade 2 good toxicity , dose subsequent cohort escalate . If grade 3 4 toxicity see one patient give dose level , two additional patient enrol level . Treatment give subcutaneously ( skin , needle ) , 3 time per week 12 week . The MTD define dose level immediately 50 percent patient experience grade 3 4 toxicity . In Cohort B ( combination IFN-A plus AZT ) , patient complete treatment Cohort A continue dose IFN-A , low , middle , high dose AZT add . In Cohort C , four newly assign patient stable prescribed dose AZT least 90 mg/m2 6 week treat dose combination Cohort B . Treatment give 12 week . IFN-A give subcutaneously 3 time week AZT give orally every 6 hour . Dose level drug increase 50 percent patient experience grade 3 4 toxicity dose level .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Recommended : Prophylaxis Pneumocystis carinii pneumonia . Allowed : Aerosol ribavirin shortterm treatment acute respiratory syncytial virus ( RSV ) . Immunization accord current recommendation Advisory Committee Immunization Practice . IVIG . Systemic ketoconazole , acyclovir , oral nystatin acute therapy . Patients must follow : HIV infection . Patients proven resistance AZT also eligible . Prior Medication : Allowed : Aerosol ribavirin . Required : Cohort C treatment : Stable prescribed dose zidovudine ( AZT ) &gt; = 90 mg/m2 least 6 week prior study entry . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : AIDS class P2B , D , E symptomatic infection . Concurrent Medication : Excluded : Hepatotoxic neurotoxic drug , immunosuppressant , antiseizure medication . Ketoconazole , fluconazole , acyclovir prophylaxis . Immunomodulators ( IVIG ) . Experimental drug . Cohort A patient : AZT clinical indication . Prior Medication : Excluded : Other antiretroviral agent ( include didanosine ( ddI ) , dideoxycytidine ( ddC ) , soluble CD4 ) within 1 month study entry . Systemic ribavirin administer retroviral therapy within 2 month study entry . Immunomodulating agent include interferon , isoprinosine , interleukin2 , lymphocyte transfusion within 4 week study entry . RBC transfusion within 4 week prior study entry . Alcohol drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Interferon Type I</keyword>
</DOC>